Day: June 11, 2024

KISSIMMEE, Fla., June 11, 2024 (GLOBE NEWSWIRE) — ECD Auto Design, is thrilled to announce the launch of the Shawnee Commission, a stunning ECD bespoke classic Jaguar E-Type. This one-of-a-kind creation is a meticulously restored and customized Jaguar E-Type Series III Coupe, combining timeless elegance with modern performance, luxury, and unique features. Please find high-resolution images and video HERE. Project Shawnee Commission showcases ECD Auto Design’s commitment to craftsmanship, innovation, and attention to detail. Every aspect of this classic Jaguar E-Type has been thoughtfully reimagined to provide an unparalleled driving experience while honoring the iconic design of the original vehicle. Project Shawnee Commission is a perfect example of ECD Auto Design expertly weaving classic styling with state-of-the-art innovation....

MONTREAL, June 11, 2024 (GLOBE NEWSWIRE) — IntelGenx Corp. (the “Company” or “IntelGenx” a subsidiary of IntelGenx Technologies Corp.) (OTCQB: IGXT; TSX: IGX), was granted protection pursuant to an order (as amended or amended and restated from time to time, the “Initial Order”) under the Companies’ Creditors Arrangement Act (the “CCAA” and the “CCAA Proceedings”) by the Superior Court of Québec (the “Court”). EY was appointed as monitor (in such capacity, the “Monitor”). On May 27, 2024, the Court granted an order (the “SISP Order”) which i) approved a sale and investment solicitation process to be conducted in respect of the business and/or assets of the Company (the “SISP”), and ii) approved the agreement of purchase and sale between IntelGenx, as vendor, and atai Life Sciences AG, as purchaser, solely for the purpose of constituting...

CSRCompiler, an SoC integration automation software solution, enables faster time-to-market and energy-efficient designs for AI inference and HPC applications at a fraction of the cost CAMPBELL, Calif., June 11, 2024 (GLOBE NEWSWIRE) — Arteris, Inc. (Nasdaq: AIP), a leading provider of system IP which accelerates system-on-chip (SoC) creation, today announced that Esperanto Technologies™, a leading developer of high-performance, energy-efficient artificial intelligence (AI) and high-performance computing (HPC) solutions based on the RISC-V instruction set, has chosen Arteris because of design familiarity with CSRCompiler for automation efficiency, error reduction and its integration capabilities. Esperanto will continue to utilize the SoC software to develop its next generation of energy-efficient solutions for AI inference...

ROSEVILLE, Minn., June 11, 2024 (GLOBE NEWSWIRE) — SecureTech Innovations, Inc. (OTC: SCTH), an emerging growth company that develops and markets cutting-edge security and safety devices, products, and technologies such as Top Kontrol and its early-stage cybersecurity and cryptocurrency technology incubator Piranha Blockchain, is pleased to announce that the Caveat Emptor designation has been removed by OTC Markets and SecureTech’s stock is now tradable on the OTC Pink Exchange. SecureTech’s President and CEO Kao Lee commented, “This is a monumental milestone for SecureTech. The Caveat Emptor removal is a direct result of our perseverance and commitment to our shareholders. SecureTech will continue diligently working to maintain the highest level of compliance and transparency with OTC Markets and the Securities and Exchange Commission.” “With...

CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel Corporation Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries...

TORONTO, June 11, 2024 (GLOBE NEWSWIRE) — (TSXV: NBM) (OTC: NBMFF)Collaboration Agreement with INNOX eco-M – Leading South Korean Chemical Material Company of Recycled Silicon PowdersSubsidiary of INNOX Holding Corp. – A Producer of Secondary Battery Materials and IT High-Tech Materials with Investment Business OperationsJointly Developing Silicon Anode Products with INNOX eco-M’s High-Purity Recycled SiliconDevelopment Priorities: Enhance Electrochemical Performance, Lower Anode Manufacturing Costs & Environmental Footprint, and Promote Supply Chain ResiliencyNEO Battery Materials Ltd. (“NEO” or the “Company”), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce a collaboration agreement with INNOX eco-M, a company renowned for...

Multitude SE: Approval of written procedure and amendments to the terms and conditions of its senior bonds due 2025 Multitude SE (the “Company“) today announces the successful completion of the written procedure that was initiated on 16 May 2024 in relation to the Company’s senior unsecured floating rate bonds with ISIN NO0012702549 (the “Bonds“), regarding certain amendments to the terms and conditions of the Bonds (the “Proposal“). A sufficient number of bondholders participated in the written procedure in order to form a quorum, and a requisite majority of the bondholders voted in favour of approving the Proposal. The amendments will become effective when the Company and the agent enter into an amendment and restatement agreement, amending and restating the terms and conditions of the Bonds...

Multitude SE: Approval of written procedure and amendments to the terms and conditions of its subordinated capital notes Multitude SE (the “Company“) today announces the successful completion of the written procedure that was initiated on 16 May 2024 in relation to the Company’s subordinated perpetual floating rate callable capital notes with ISIN NO0011037327 (the “Notes“), regarding certain amendments to the terms and conditions of the Notes (the “Proposal“). A sufficient number of noteholders participated in the written procedure in order to form a quorum, and a requisite majority of the noteholders voted in favour of approving the Proposal. The amendments will become effective when the Company and the agent enter into an amendment and restatement agreement, amending and restating the terms...

DENVER, June 11, 2024 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that its patented, cell-directed, extracorporeal Selective Cytopheretic Device (SCD) is being featured in two presentations at the 42nd Vicenza Course AKI-CRRT-ECOS and Critical Care Nephrology conference today, June 11, 2024. The International Vicenza Course – a scientific program that integrates industry-sponsored symposia, meet-the-expert sessions and short presentations – is being held June 11-13 in Vicenza, Italy. “The prestigious International Vicenza Course is known for showcasing breakthroughs in the field of extracorporeal organ support. It is an honor to be invited to showcase our...

PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end Carlsbad, CA, June 11, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for patent application number 3,174,137 titled, “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors.” This patent covers the composition of PALI-2108, the Company’s orally administered, locally acting colon-specific Phosphodiesterase-4 (PDE4) inhibitor...